Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis
- 19 September 2013
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 48 (10) , 1152-1159
Abstract
Objective. Inflammatory bowel disease (IBD) is a chronic debilitating disease associated with severe damage to the intestinal mucosa. Glucagon-like peptide-2 (GLP-2) is a potent and specific gastrointestinal growth factor. GLP-2 released from enteroendocrine cells is inactivated by dipeptidyl peptidase-4 (DPP-4). The aim of this study was to examine whether the DPP-4 inhibitor anagliptin improves experimental murine colitis. Material and methods. Male C57BL/6 mice aged 8 weeks were exposed to 1.5% dextran sulfate sodium (DSS) in drinking water for 7 days to induce experimental colitis. Anagliptin (0.1% in diet) was administrated from 2 days before the beginning of DSS to 7 days after the end of DSS. Changes in body weight and disease activity index were evaluated daily. Histological colitis severity, cellular proliferation and gene expression were determined in colonic tissues. Results. Treatment with anagliptin clearly improved body weight loss and disease activity index in the recovery phase. Histological score in the DSS + anagliptin group at day 14 was significantly lower than that in the DSS alone group. Treatment with anagliptin increased the Ki67-positive rate at days 10 and 14, and tended to increase insulin-like growth factor-1 mRNA expression in the DSS + anagliptin group. Conclusion. In this model of experimental colitis, the DPP-4 inhibitor anagliptin facilitated the restoration of mucosal damage, thereby resulting in the acceleration of healing. These findings suggest a new and novel therapeutic approach for the treatment of IBD.Keywords
This publication has 24 references indexed in Scilit:
- Metabolic impact of glucagon deficiencyDiabetes, Obesity and Metabolism, 2011
- Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndromeSurgery, 2011
- Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2011
- Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasomeGut, 2010
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?Trends in Pharmacological Sciences, 2009
- Morphological adaptation with preserved proliferation/transporter content in the colon of patients with short bowel syndromeAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in miceFrontiers in Bioscience-Landmark, 2008
- Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 DiabetesDiabetes Care, 2007
- Immunopathogenesis of inflammatory bowel diseaseWorld Journal of Gastroenterology, 2007
- Insulin-like Growth Factor-I Partially Attenuates Colonic Damage in Rats with Experimental Colitis Induced by Oral Dextran Sulphate SodiumScandinavian Journal of Gastroenterology, 1998